Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

© 2017 The British Pharmacological Society The terms ‘licensed’, ‘unlicensed’, and ‘off-label’, often used in relation to marketing and prescribing medicinal products, may confuse UK prescribers. To market a medicinal product in the UK requires a Marketing Authorization (‘product licence’) for specified indications under specified conditions, regulated by the Medicines and Healthcare products Regulatory Agency (MHRA). The Marketing Authorization includes the product's agreed terms of use (the ‘label’), described in the Summary of Product Characteristics (SmPC). Prescribing a licensed product outside those terms is called ‘off-label’ prescribing. Products for which no-one holds a UK Marketing Authorization are unlicensed. Prescribers can prescribe authorized products according to the conditions described in the SmPC (‘on-label’) or outside those conditions (‘off-label’). They can also prescribe unauthorized products, even if they are unlicensed in the UK, if they are licensed elsewhere or if they have been manufactured in the UK by a licensed manufacturer as a ‘special’. The complexities of this system can be understood by considering the status of the manufacturer of the product, the company that markets it (which may or may not be the same), the product itself, and its modes of use, and by emphasizing the word ‘authorized’. If a Marketing Authorization is granted to the supplier of a product, it will specify the authorized modes of use; the product will be prescribable as authorized (i.e. ‘on-label’) or in other modes of use, which will all be off-label. Unlicensed products with no authorized modes of use can be regarded as ‘unauthorized products’. All ‘specials’ can be regarded as authorized products lacking authorized modes of use.

Original publication

DOI

10.1111/bcp.13394

Type

Journal article

Journal

British Journal of Clinical Pharmacology

Publication Date

01/12/2017

Volume

83

Pages

2615 - 2625